Karna D. Shinde invests in Navaux

OneCell Diagnostics Inc. Diagnostics has raised $16 million in a Series A funding round led by Celesta Capital, alongside Tenacity Ventures, Cedars-Sinai, Eragon and Singularity Ventures. The funding will drive the US expansion of its cutting-edge liquid biopsy test, OncoIndx Alfa, designed to detect circulating tumor cells for precision cancer diagnosis. Founded in 2021, the startup utilizes next-generation sequencing, AI/ML, and data analytics to create advanced biomarkers. Collaborating with AIIMS, Tata Memorial Centre, and institutions like Harvard and Stanford, OneCell has already tested its biopsy technology on 10,000 patients in India, making strides in cancer care innovation. #OneCellDiagnostics #CancerInnovation #SeriesAFunding #OncoIndxAlfa #BiotechStartup #PrecisionDiagnostics #HealthcareTech #AIinMedicine #CancerCare #Startup77

4baseCare Secures $6 Million in Series A Round Led by Yali Capital In a significant boost for the precision oncology sector, healthcare startup 4baseCare has successfully raised $6 million in its Series A funding round, with Yali Capital leading the investment. Founded in 2018 by Hitesh Goswami and Kshitij Rishi, 4baseCare has been at the cutting edge of genomic-based cancer treatment. Their flagship product, Indiegene, is the world’s first cancer gene panel specifically designed for the Indian population, making a substantial impact on over 10,000 cancer patients across Southeast Asia. The newly acquired funds will enable 4baseCare to expand its operations, set up genomics laboratories in the Philippines, Nepal, and Dubai, and enhance its advanced data analytics and clinical insights capabilities. This expansion will not only bolster the company’s presence in Asia and the Middle East but also further its mission to revolutionize cancer care with precision and innovation. Stay tuned for more updates as 4baseCare continues to push the boundaries of healthcare technology! Read More: https://lnkd.in/gmt7h9_E #Healthcare #PrecisionOncology #Genomics #FundingNews #4baseCare #SeriesAFunding #Innovation #CancerCare #DigitalHealth #MedicalTech #Expansion #YaliCapital

🎉 Thrilled to share that Oncoliq has been featured in a Venture Capital Post article! 🚀 As we focus on launching our product by early 2026, we want to keep sharing the importance of early detection in significantly improving survival rates. Current screening methods are inaccessible to many or not sensitive enough to catch cancers early 👩🔬🏥. Oncoliq's groundbreaking blood test detects microRNA, tiny molecules in the early stages of tumor development. This is precisely what differentiates us from competitors who rely on detecting ctDNA, which only appears in the bloodstream during later stages of cancer. "At Oncoliq, we've developed a solution that can change the landscape of cancer diagnostics, making it possible to detect cancer early, easily, and at a low cost," says Marina Simian, to the Venture Capital Post team. 🚀 Join Oncoliq if you feel inspired about shaping the future of cancer detection and saving lives! Read the full article here and comment your thoughts!👉 https://lnkd.in/ddxKA5gJ Thank you [Venture Capital Post] #Oncoliq #Biotechnology #EarlyDetection #LiquidBiopsy #HealthTech #InnovationInHealthcare #VentureCapital #HealthcareInvesting #CancerDiagnosis #CancerMortality #HealthStartups

🚀 Thrilled to share that Oncoliq’s groundbreaking journey is featured in Venture Capital Post! 🚀 Cancer continues to claim millions of lives, often due to late-stage diagnoses. At Oncoliq, we’re determined to change this through our scalable, decentralized microRNA detection technology—bringing the power of early cancer detection to communities worldwide. This article reveals the depth of our mission and the steps we’re taking to reduce global cancer mortality. As we accelerate our growth, we’re eager to connect with visionary investors and partners ready to make an impact. 👉 Don’t miss the full story here: Life-Saving Tech: Oncoliq's Scalable, Decentralized Solution to Reduce Cancer Mortality https://lnkd.in/ddxKA5gJ Join us if you're interested in being part of this life-saving innovation journey. Together, we can drive real change. #Oncoliq #Biotechnology #CancerDetection #HealthTech #Innovation #StartupFunding #VentureCapital #BusinessGrowth #EarlyDetection

🌍💡 Spotlight on Europe’s Emerging CancerTech Startups 💡🌍 🎗 The fight against cancer is evolving, and Europe is at the forefront with a wave of #innovative startups making significant strides in cancer #technology. From early detection to personalized treatment, these companies are harnessing cutting-edge tech to transform patient outcomes. 🌟 As we witness these exciting #developments, it's clear that #collaboration and innovation will be key to overcoming one of humanity's greatest challenges. Here are some emerging cancer tech startups in Europe, including: Kuano, Antiverse, Awell, Careology, CliniNote, DeepLife, Concr, Orakl Oncology, Panakeia, PreComb, Sonrai, Ignota Labs, Neuroute, Sycai Medical, Alvie Health, RECEPTOR.AI, Tailor. bio, TrialHub, DiaDeep, Onocochain To share your startup story write us on - [email protected] #Cancerstartup #Europeanstartup #startup

OneCell Diagnostics Inc. raised $16 million in Series A funding led by Celesta Capital, with participation from Tenacity Ventures and others. The funds will support the U.S. expansion of OncoIndx Alfa, a cutting-edge liquid biopsy test for detecting circulating tumor cells. Established in 2021, the startup leverages AI/ML, advanced sequencing, and bioinformatics to enhance cancer diagnostics and treatment. - $16M funding led by Celesta Capital. - Focus on OncoIndx Alfa for cancer detection. - U.S. market expansion plans. - Partnerships with AIIMS and Tata Memorial Centre. #OneCellDiagnostics #StartupFunding #Zedvox #ZedvoxNews #LiquidBiopsy #CancerCare #PrecisionOncology #StartupIndia #HealthTech #MedicalInnovation #CancerDiagnostics #FundingAlert #SeriesAFunding #Oncology #HealthcareInnovation #AIInHealthcare #Bioinformatics #InvestmentNews #HealthCareTech #Biotech #InnovativeDiagnostics #TechGrowth #USExpansion #AdvancedSequencing #AI #ML #CTCDetection #HealthcareStartups #FundingNews #CancerTreatment #DiagnosticsStartup

Healthtech startup ErlySign secured funding led by Ashish Kacholia to advance its mission of revolutionizing early oral cancer detection. The funds will be used to complete clinical trials, secure CDSCO approvals, and launch its innovative oral cancer detection kit. Additionally, the company plans to invest in R&D, team expansion, and filing new patents. Founded in 2019 by Shubhendra Singh Thakur and Deovrat Begde, ErlySign focuses on early oral cancer detection. Its flagship biomarker-based test kit identifies precancerous conditions within 15 minutes using a non-invasive saliva sample. Read more about this: https://lnkd.in/gzKPc-Ut #ErlySign #HealthTech #FundingNews #StartupIndia #StartupFunding #BusinessNews

VitroScan, a PLNT startup that’s apart of unlock_ Incubation, was awarded 1.9M by Biotech Booster! 🎉 This grant is to deliver chemotherapy response prediction for ovarian cancer patients. VitroScan has developed ChemoPredict, a predictive tumor testing service, that revolutionizes treatment options for ovarian cancer patients. The technology platform identifies chemotherapy-resistant versus chemotherapy-sensitive patients, demonstrating its capability to select effective and cost-efficient treatment strategies for individual patients. Biotech Booster’s funding will enable VitroScan to leverage the value of know-how, scientific and clinical evidence, and existing partnerships to prepare for clinical implementation and ensure the services meet the quality and regulatory standards required for bringing the services to the patients. Read the full article via https://lnkd.in/exSPGy-R #funding #startup #scaleup #biotechbooster #lifescience #plntleiden

Fantastic program open for innovators in the Cancer space, important themes are: Equitable Care For All Clinical Trial Acceleration Connected & Individualized Care – Care beyond the clinic

It’s exciting to see experts from outside pharma stepping into the industry. LinkedIn co-founder Reid Hoffman and cancer researcher Siddhartha Mukherjee just launched Manas AI, an AI-driven startup with $24.6M in funding, aiming to transform cancer treatments. As Mukherjee says: “AI was a mechanism to scale—vastly—the kinds of work that we were doing in any one laboratory, and across diseases.” This is a huge step for AI in drug discovery. Thoughts on more cross-industry collaborations like this? https://lnkd.in/eXx75jM7 #AIinPharma #DrugDiscovery #CancerResearch #HealthTech #PharmaInnovation #ArtificialIntelligence #Biotech #FutureOfMedicine #Startups #Innovation